# PRECISE, a Study to Gather More Information About Bone Fractures and Survival in Castration-resistant PRostate Cancer (CRPC) patiEnts Treated With Radium-223 in Routine Clinical practIce in SwedEn

> **NCT04256993** · — · COMPLETED · sponsor: **Bayer** · enrollment: 1434 (actual)

## Conditions studied

- Metastatic Castration-Resistant Prostate Cancer

## Interventions

- **DRUG:** Radium-223 dichloride (Xofigo, BAY88-8223)
- **DRUG:** Other standard care

## Key facts

- **NCT ID:** NCT04256993
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-15
- **Primary completion:** 2021-06-01
- **Final completion:** 2021-06-01
- **Target enrollment:** 1434 (ACTUAL)
- **Last updated:** 2024-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04256993

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04256993, "PRECISE, a Study to Gather More Information About Bone Fractures and Survival in Castration-resistant PRostate Cancer (CRPC) patiEnts Treated With Radium-223 in Routine Clinical practIce in SwedEn". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04256993. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*